The fully virtual, decentralized phase IIIb BATURA clinical trial demonstrated that the as-needed use of albuterol-budesonide significantly reduced the risk of severe asthma exacerbations compared with albuterol alone in patients with mild, uncontrolled asthma. This combination inhaler allows patients to target both bronchoconstriction and underlying inflammation immediately in response to symptoms, reducing the risk of severe exacerbations even in patients with infrequent symptoms. The safety profiles between the two treatment arms showed comparable rates of adverse events, with the most common adverse events being upper respiratory tract infections, COVID-19, and nasopharyngitis.

Source: New England Journal of Medicine